Australia's Neuren Pharmaceuticals hits record high on successful drug trial

Neuren Pharmaceuticals

17/12/2023 23:59

** Shares of Neuren Pharmaceuticals  NEU.AX  rise as much as
32.4% to A$22.700, their highest level ever     
    ** Biopharmaceutical co says Phase 2 clinical trial of
NNZ-2591 drug in children with Phelan-McDermid syndrome shows
significant results
    ** Improvement observed by both clinicians and caregivers
from treatment, across multiple efficacy measures - co
    ** Phelan-McDermid syndrome affects communication,
behaviour, cognition/learning and socialisation
    ** Stock set for best day since Dec. 7, 2021, if gains hold
    ** 800,675 shares change hands, compared with the 30-day
average volume of 657,443
    ** NEU up 115.6% YTD as of last close

 (Reporting by Adwitiya Srivastava in Bengaluru)
 ((Adwitiya.Srivastava@thomsonreuters.com;))